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Abstract
A selective method based on high performance liquid chromatography with electrochemical detection (HPLC-ECD) was developed to
enable simultaneous detection of 8-oxo-7,8-dihydroguanine (8-oxoGua) and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodGuo), products
of DNA oxidative damage, in the presence of uric acid (UA), a strong interferent in their electrochemical detection. The method developed
consists of HPLC isocratic elution with amperometric detection on a glassy carbon electrode, enabling a detection limit for 8-oxoGua and
8-oxodGuo lower than 1 nM in standard mixtures. Detection of low concentrations up to 25 nM of 8-oxoGua and 8-oxodGuo in the presence
of UA in a 104-fold higher concentration was achieved after one-step solid phase extraction (SPE). The method was tested with urine samples
and it was possible to detect and quantify the presence of 8-oxoGua, and to confirm that UA was eliminated after uricase degradation and
SPE. The LOD found in urine samples was about 80 nM, a value higher than in standard mixtures, due to the increase of background current
in the urine matrix. The results presented here contribute to the development of a methodological approach to simultaneous determination of
8-oxoGua and 8-oxodGuo in urine samples.
© 2003 Elsevier B.V. All rights reserved.
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1. Introduction
Oxidative DNA damage caused by oxygen-free radi-
cals leads to multiple modifications in DNA, including
base-free sites and oxidised bases that are potentially mu-
tagenic [1–7]. The major product of DNA oxidative dam-
age is 8-oxo-7,8-dihydroguanine (8-oxoGua) (Scheme 1a)
which is the product of oxidation of guanine, the most
easily oxidised base in DNA [8]. This modified base
is highly mutagenic [9,10] due to its loss of base pair-
ing specificity [11–13]. Since it was first reported two
decades ago [14], 8-oxoGua, namely its deoxynucleo-
side 8-oxo-7,8-dihydro-2′deoxyguanosine (8-oxodGuo)
(Scheme 1b), has been the subject of intensive investigation
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and became widely accepted as a biomarker of oxidative
DNA damage and cellular oxidative stress [15–17]. Ele-
vated levels of 8-oxodGuo were found in the urine and
lung tissues of smokers [18,19] as well as in body fluids
and DNA from human tissues of patients with disorders
such as cancer, atherosclerosis, chronic hepatitis, cystic
fibrosis, diabetes, acquired immunodeficiency syndrome,
neurodegnerative and age-related diseases [17,20–23].
Two main approaches to assess this oxidative DNA
damage exist, one being the measurement of 8-oxoGua
or 8-oxodGuo content in DNA isolated from tissues that
would represent steady-state levels arising from the bal-
ance between oxidative damage and enzymatic repair [16].
However, measurements of 8-oxoGua in cellular DNA re-
sulted in a wide range of values, from about 0.1 to 100
8-oxoGua/105 G [6,17,24], attributed to possible artifactual
oxidation of unmodified guanine during work-up proce-
dures of DNA isolation [25–30]. This raised concern about
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Scheme 1. Chemical structures of: (a) major tautomers of 8-oxo-7,8-dihydroguanine (8-oxoGua) in neutral pH; (b) 8-oxo-7,8-dihydro-2′-deoxyguanosine
(8-oxodGuo) and (c) uric acid (UA).
the validity of the analytical methods employed and led to
the investigation of optimal methodologies for 8-oxoGua
and 8-oxodGuo measurements in DNA [31–33]. A sec-
ond approach has been the measurement of urinary levels
of 8-oxodGuo that is widely accepted as a biomarker of
“whole body” oxidative DNA damage [16,34] since urinary
8-oxodGuo could arise not only from excision repair of
oxidised DNA but also, maybe largely, from hydrolysis of
oxidised guanine nucleotides in the DNA precursor pool
[34,35] and, in a further possibility, from DNA breakdown
products upon enzymatic action on dead cells [36]. Initially,
urinary 8-oxoGua was rejected as a biomarker of DNA dam-
age because studies on rat urine [20,37] showed that diet
could contribute significantly to its urinary levels and be a
confusing factor. However, recent studies in humans [22,23]
reveal that urinary levels of 8-oxoGua and 8-oxodGuo are
not dependent on diet and taking into account that the major
DNA repair pathway excises 8-oxoGua and not 8-oxodGuo
[38–40], maybe urinary levels of 8-oxoGua could better
reflect oxidative DNA damage than 8-oxodGuo. Despite
all the controversy, assessment of urinary levels of both
8-oxoGua and 8-oxodGuo may provide a non-invasive ap-
proach to evaluate the DNA repair capability in individuals
and be used as biomarkers of cellular oxidative stress.
Various methods to detect 8-oxodGuo urinary steady-state
levels in humans were found [14,41–47] the majority report-
ing values below 10 ng 8-oxodGuo mg−1 creatinine (excre-
tion rates that correspond to concentrations below 30 nM),
with a few publications reporting concentrations still below
100 nM [47–50]. Only a few methods were found to be able
to detect human urinary 8-oxoGua [37,41,44,49,51] and
even fewer quantified it, reporting levels also below 100 nM
[49,51], with the exception of one that presented a concen-
tration around 583± 376 nM [44]. In all studies that quan-
tified simultaneously 8-oxoGua and 8-oxodGuo, levels of
8-oxoGua were higher than those obtained for 8-oxodGuo in
agreement with the studies indicating that the main DNA re-
pair pathways excise the base and not the nucleoside [39,40].
At present, high performance liquid chromatography
with electrochemical detection (HPLC-ECD) is the most
commonly used technique to assess urinary 8-oxodGuo, but
HPLC with tandem mass spectrometry (HPLC-MS/MS)
is increasingly being used, showing high sensitivity and a
better specificity. However, HPLC-ECD is easier to use and
less demanding of resources. There is a significant lack of
HPLC-ECD based methods for 8-oxoGua detection in hu-
man urine, despite 8-oxoGua being also electrochemically
detectable [52] at a lower potential than 8-oxodGuo [53].
One possible reason for this is that chromatographic sepa-
ration of 8-oxoGua is problematic due to its low retention
on C18 reversed phase columns and to strong interference
with another analyte that co-elutes with it, namely uric acid
(UA), a purine with a structure very similar to 8-oxoGua
(Scheme 1c), also electroactive and excreted in urine at con-
centrations around 0.5 mM (25–70 mg l−1) [54], 104-fold
higher than 8-oxoGua and 8-oxodGuo steady-state lev-
els. This introduces serious problems for achieving a high
enough separation factor and sensitivity requiring complex,
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costly and time-consuming urine clean-up procedures. This
paper describes an HPLC-ECD method developed for si-
multaneous detection of 8-oxoGua and 8-oxodGuo in the
presence of excess UA, applying a solid phase extraction
(SPE) procedure. The same SPE approach was used for pre-
liminary qualitative analysis of 8-oxoGua and 8-oxodGuo
in human urine samples.
2. Experimental
2.1. Chemicals
8-oxo-7,8-Dihydroguanine (8-oxoGua, C5H5N5O2,
MW = 167.13), 8-oxo-7,8-dihydro-2′-deoxyguanosine
(8-oxodGuo, C10H13N5O5, MW = 283.2), uric acid sodium
salt (C5H3N4O3Na, MW = 190.1) and uracil (C4H4N2O2,
MW = 112.1) of analytical grade were obtained from
Sigma, Steinheim, Germany and used without further pu-
rification. Uricase from Bacillus fastidiosus 16.2 U mg−1,
EC 1.7.3.3, was obtained from Fluka, Steinheim, Germany.
Sodium dihydrogen phosphate monohydrate, di-sodium
hydrogen phosphate dihydrate and ammonium sulphate of
analytical grade were obtained from Merck, Darmstadt, Ger-
many. Methanol of HPLC gradient grade was also obtained
from Merck. Purified water obtained through a Milli-Q wa-
ter purification system (resistivity > 18 M cm) from Mil-
lipore, Bedford, USA, was used to prepare all solutions.
HPLC mobile phase buffers were filtered and degassed un-
der vacuum, through 0.2m NL 16 membranes from Schle-
icher and Schuell, Dassel, Germany.
2.2. Standard solutions preparation
Stock solutions of 8-oxodGuo and UA were prepared by
dissolving the powder from Sigma in purified water to final
concentration 100M. A stock solution of 8-oxoGua was
prepared by dissolving the powder from Sigma in ultrapure
water to a final concentration of 35M. To assure total solu-
bility of 8-oxoGua, 20l of 8 M NaOH solution were added
to give final pH 9–10, verified with pH-indicator paper.
Stocks from each compound were further diluted to 1M in
pH 6.1 50 mM phosphate buffer and stored at 4 ◦C for further
use. From 1M stock solutions, equimolar standard mix-
tures of 8-oxoGua, 8-oxodGuo and UA were prepared in pH
6.1 50 mM phosphate buffer and used as working standards
in the range 2.5–250 nM for electrochemical detection and
in the range 100 nM to 10M for UV-spectrophotometric
detection calibration curves.
2.3. SPE procedure for 8-oxoGua and 8-oxodGuo
extraction in the presence of excess UA
2.3.1. Without previous uricase addition for UA
degradation
Standard solutions of 0.6 mM UA prepared in pH 6.1
50 mM phosphate buffer were spiked with appropriate
volumes of a 1M equimolar standard mixture of 8-oxoGua
and 8-oxodGuo to give four mixtures with final concen-
trations of 25, 50, 100 and 250 nM of each analyte. Of
each mixture, 3 ml were applied on SPE C18 octade-
cyl phase cartridges (Chromabond C18 500 mg/3 ml from
Macherey-Nagel, Germany) previously conditioned with
3 ml × 3 ml of MeOH, followed by 3 ml of H2O and
3 ml × 3 ml of pH 6.1 50 mM phosphate buffer at a flow
rate of ∼2 ml min−1. The filtrate solutions were then col-
lected for further analysis, the cartridges were washed with
3 ml of pH 6.1 50 mM phosphate buffer and the wash so-
lutions were also collected. Elution from the cartridges was
performed with 3 ml of pH 6.1 50 mM phosphate buffer
containing 20% MeOH at a flow rate∼1 ml min−1. Aliquots
of 10l of the eluate solutions were directly injected into
the HPLC system. Another type C18 octadecyl phase SPE
cartridges (Chromabond C18ec, where ec means endcapped
silanol groups, also from Macherey-Nagel, Germany) was
tested for pre-treatment of urine samples. Unlike in the C18
SPE cartridges, in the C18ec cartridges the residual –SiOH
groups of immobilised octadecyl chains were reacted with
smaller alkylsilane reagents and so lost their capacity to
interact with polar groups of some analytes. This difference
in capping chemistry leads to the differences in selectivity
observed between C18 and C18ec SPE extraction cartridges.
2.3.2. With previous uricase addition for UA degradation
Five milliliters of the standard mixture of 0.6 mM UA
were prepared in 0.1 M phosphate buffer (pH 8.2) and spiked
with 8-oxoGua and 8-oxodGuo to 100 nM final concentra-
tion and 10l of a 20 mg ml−1 uricase solution were added.
The solution was kept at room temperature (∼25 ◦C) in a
stream of pure oxygen for 5 min to reach full enzymatic
degradation of uric acid, which was confirmed by spec-
trophotometric enzymatic assay at 292 nm. After the enzy-
matic digestion of UA, 3 ml of the mixture were subjected
to the same SPE procedure as described in Section 2.3.1.
2.4. Urine collection and clean-up procedure for
8-oxoGua and 8-oxodGuo analysis
The method developed was tested in urine samples from
children (age between 3 and 8 years old) with metabolic
disorders that may lead to an oxidative stress condition and
urines from 65 to 75-year-old persons suffering from cog-
nitive deficit. Urine was collected, divided into 10 ml frac-
tions and stored at −20 ◦C. For analysis, urine samples
were thawed at room temperature and submitted to vortex
homogenisation. Salting-out of proteins was performed by
adding ∼2 g of ammonium sulphate per 10 ml urine fol-
lowed by centrifugation at 2200× g for 10 min. The super-
natant was removed and the pH of the urine was adjusted
with sodium hydroxide to a final value of 7–8, which was
checked with pH indicator-paper. From a 20 mg ml−1 uri-
case solution prepared in pH 8.2 0.1 M phosphate buffer,
1.5l were added to 1 ml of urine sample and the mixture
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kept at room temperature (∼25 ◦C) under a stream of pure
oxygen for 5 min. After uric acid degradation, urines were
again centrifuged at 2200 × g for 5 min. From the super-
natant, a fraction of 3 ml was submitted to the SPE proce-
dure described in Section 2.3.1.
2.5. Instrumentation
A Waters 2690 Alliance system with a Photodiode Ar-
ray Detector 996 (PDA 996) in series with a CONCORDE
Electrochemical Detector from Waters Corporation, Milford,
USA, was used. The HPLC separation was performed in a
reverse phase LC-18-S Supelcosil analytical column with
15 cm × 4.6 mm ID, 5m bonded spherical silica, 100 Å
pore size, in series with a LC-18-S Supelguard 2 cm ×
4 mm ID guard column from Supelco, Bellefonte USA. All
chromatograms presented were acquired by a Millenium 32
Chromatography Manager from Waters Corporation. Origin
version 6.0 from Microcal Software was used for the pre-
sentation of all other plots reported in this work.
2.5.1. Chromatographic conditions
Unless otherwise stated, phosphate buffer 50 mM, pH 6.1
with 6% MeOH and 2 mM KCl, of final pH 6.2 was used as
mobile phase. Elution was in isocratic mode at 1 ml min−1
flow rate. The guard column and analytical column were
kept at T = 30 ◦C together with the electrochemical flow
cell in a Faraday cage with a thermostatic oven.
2.5.2. Electrochemical conditions
The electrochemical cell was a VT-03 flow cell from
Antec Leyden, Zoeterwoude, Netherlands, of a confined
wall-jet design, in a three-electrode configuration: a glassy
carbon working electrode with 2 mm diameter, an in-situ
Ag/AgCl reference electrode and a stainless steel auxiliary
electrode. The in-situ Ag/AgCl reference electrode, referred
to here as ISAAC (in-situ Ag/AgCl) is in direct contact with
the mobile phase that contains 2 mM chloride ions (2 mM
KCl). There is a difference of+0.19 V between the potential
of the Ag/AgCl reference electrode saturated with 3 M KCl
and the ISAAC reference electrode in contact with 2 mM
KCl. Thus, for an application running at E = +0.7 V ver-
sus Ag/AgCl saturated with 3 M KCl, the potential setting
using ISAAC should be E = +0.51 V. All potentials are
referred to the ISAAC reference electrode and unless oth-
erwise stated, the cell potential was set at +0.5 V versus
ISAAC (+0.69 V versus Ag/AgCl reference electrode).
3. Results and discussion
3.1. Comparison of spectrophotometric and
electrochemical detection
Low concentrations up to 2.5 nM of 8-oxoGua and
8-oxodGuo in the presence of UA are selectively and
sensitively detected by amperometry but the spectrophoto-
metric/UV signal is badly distinguished from the noise for
such low concentrations. Electrochemical signals obtained
from injection of a 5 nM standard equimolar mixture of UA,
8-oxoGua and 8-oxodGuocould also be well distinguished
from noise whereas, for the same concentration, UV signals
for the mixture cannot be detected at all. UV signals with a
similar signal to noise ratio were obtained only for mixtures
with concentrations above 500 nM, i.e. a 100-fold higher
concentration.
Standard mixtures in the concentration range 2.5–250 nM
were injected in order to obtain calibration curves for elec-
trochemical signals. The limit of detection (LOD) based
on 3.3 × S.D./slope of calibration curve for 8-oxoGua
(Ip (nA) = 0.00492 + 0.01178× 8-oxoGua (nM); R2 = 1;
S.D. = 0.00215, N = 7, P < 0.0001) was 0.6 nM while
for 8-oxodGuo (Ip (nA) = 0.00125+ 0.0031× 8-oxodGuo
(nM); R2 = 0.99999; S.D. = 8.50236 × 10−4, N = 7,
P < 0.0001) was 0.9 nM. For both analytes in standard
mixtures, LOD was lower than 1 nM (10 fmol for each an-
alyte injected). Calibration curves for spectrophotometric
UV signals at λ = 249 nm were obtained from injection
of standard mixtures in the concentration range 100 nM to
10M. The LOD of 179 nM for 8-oxoGua and 193 nM for
8-oxodGuo confirm that electrochemical detection is more
sensitive than UV detection by a factor of 300 for 8-oxoGua
and 200 for 8-oxodGuo. The HPLC-ECD method presented
permits 8-oxoGua and 8-oxodGuo detection in the pres-
ence of uric acid, a strong interferent in the electrochemical
detection of these substances due to its similar oxidation
potential, in less than 12 min.
3.2. Hydrodynamic voltammograms
Hydrodynamic voltammograms for 8-oxoGua, 8-oxodGuo
and UA, obtained by running a mixture of the three an-
alytes at a working potential in the range E = +0.2 to
E = +0.6 V versus ISAAC are presented in Fig. 1. The op-
timum working potential, obtained from the hydrodynamic
voltammograms for the value corresponding to maximum
current was +0.5 V for all three analytes, and is indicated
by an arrow in Fig. 1A. Above this potential and for the flow
rate used, the current becomes diffusion limited. Fig. 1A
shows clearly that the diffusion-limited current is four times
higher for 8-oxoGua than for 8-oxodGuo but the total charge
transferred, Fig. 1B, in the oxidation of 8-oxoGua is just
two times higher than that of 8-oxodGuo. The difference
can be due to the presence of a sugar in the 8-oxodGuo
molecule that increases the difficulty to reach the electrode
surface. According to these results, the working potential
for amperometric detection of 8-oxoGua and 8-oxodGuo
was set at +0.5 V versus ISAAC. The half wave potential,
E1/2 = +0.3 V (+0.49 V versus Ag/AgCl reference elec-
trode) obtained in this study is in good agreement with pre-
vious work on 8-oxoGua electrochemical oxidation at glassy
carbon electrodes by differential pulse voltammetry [52].
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Fig. 1. Hydrodynamic voltammograms of 8-oxoGua (), 8-oxodGuo () and UA (
) obtained by running 10l of a 250 nM equimolar mixture of UA,
8-oxoGua, 8-oxodGuo at different working electrode potentials: (A) peak intensity vs. working potential; (B) peak charge vs. working potential. The
arrow indicates the optimum working potential. ISAAC (in-situ Ag/AgCl) is −0.19 V vs. Ag/AgCl reference electrode.
3.3. Selection of mobile phase pH to improve
separation factor
The effect of the mobile phase pH on the relative reten-
tion of UA, 8-oxoGua and 8-oxodGuo was studied by de-
termination of their retention factors as a function of pH in
the pH range 4.5–7 as shown in Fig. 2. UA has a behaviour
that is typical of an acid with the pH at the inflection point
Fig. 2. Retention factor (k) dependence on mobile phase pH for 8-oxoGua
(), 8-oxodGuo (
) and UA (), obtained from 10l injection of a
250 nM equimolar mixture of UA, 8-oxoGua and 8-oxodGuo. Retention
factor calculated as: k = (tR − t0)/t0, where tR is the analyte retention
time and t0 is the elution time of an unretained analyte (t0 = 1.96 min
obtained from uracil injection with MeOH/H2O 66/34 as mobile phase).
The arrow indicates the pH chosen for the mobile phase.
of the sigmoidal curve corresponding to its pKa in aqueous
solution. From this experimental curve, UA pKa is about 5.5
which is in good agreement with the UA published value
of pKa equal to 5.6 [54]. Above this pH, UA exists pre-
dominantly as the urate ion, much more soluble in water
and so, its retention on column decreases, as confirmed by
the curve in Fig. 2. The relative dependence of 8-oxoGua
and 8-oxodGuo retention factor on pH is very similar with
no significant variation with pH. Experimental values for
8-oxoGua pKa are scarce, in part due to its insolubility in
water. Nevertheless, from predicted pKa values of various
neutral and charged tautomers of 8-oxoGua in aqueous phase
(pKa1 = 0.22 (N3), pKa2 = 8.69 (N1), pKa3 = 11.93 (N9)
[13]) it can be concluded that 8-oxoGua as well 8-oxodGuo
is neutral below pH 8. This explains well their retention de-
pendence with mobile phase pH, plotted in Fig. 2.
From previous studies [52] it is also known that the
8-oxoGua peak current increases with electrolyte pH until
pH 10 and thus, a buffer with a pH as high as possible
would be ideal for 8-oxoGua detection. Since the operation
limit of the analytical column is pH 7.5 and 7.0 did not lead
to much signal improvement in the separation factor, pH
6.2 phosphate buffer was chosen as mobile phase.
3.4. Electrochemical detection of 8-oxoGua and
8-oxodGuo in presence of excess UA
As stressed before, in human urine, the concentration of
UA is 104-fold higher than basal levels of 8-oxoGua and
8-oxodGuo which makes their detection, namely 8-oxoGua,
very difficult due to the proximity of UA and 8-oxoGua
retention times. With a view to developing a methodology
for overcoming this problem in urine samples, solid phase
extraction of standard solutions of 8-oxoGua and 8-oxodGuo
in the presence of excess UA was carried out to see whether
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Fig. 3. Chromatograms obtained from 10l injection of a standard mixture of UA 0.6 mM spiked with a mixture of 8-oxoGua and 8-oxodGuo to final
concentration 100 nM of both: (1) without addition of uricase solution to the mixture; (2) with addition of uricase solution to the mixture for UA digestion;
(A) without SPE of the mixture; (B) after SPE treatment of the mixture. Mobile phase: 50 mM phosphate buffer + 6% MeOH + 2 mM KCl, final pH 6.2.
UA could be eliminated by SPE without significant loss of
8-oxoGua and 8-oxodGuo.
In Fig. 3 are presented chromatograms obtained from a
standard solution of 0.6 mM UA spiked with a mixture of
8-oxoGua and 8-oxodGuo to give final concentration 100 nM
of both. Fig. 3(1-A) presents the chromatogram obtained for
the mixture before SPE treatment and Fig. 3(1-B), the same
mixture after SPE treatment by the procedure described in
Section 2.3.1. It was found (UV data not shown), that 97%
of UA is removed by this SPE procedure. The HPLC de-
termination of UA in the filtrate and wash solutions (see
Section 2.3.1), showed that UA was partially eliminated in
the filtrate (∼33%) and wash (∼64%) solutions (UV data not
shown). This indicated that UA is weakly retained (∼3%)
in this hydrophobic sorbent, as expected, since at pH 6 UA
exists mainly as urate anion that is more soluble in the
buffer aqueous phase. The amount of UA (∼3%) that was
not removed by SPE still gave a strong electrochemical sig-
nal but the resolution between 8-oxoGua and UA peaks,
Fig. 3(1-B), is much better than before SPE, Fig. 3(1-A),
whereas 8-oxoGua appears as a shoulder following the UA
peak. The addition of uricase solution to the mixture before
SPE treatment allows the complete removal of UA with-
out degradation of 8-oxoGua and 8-oxodGuo, Fig. 3(2-A).
Control experiments were performed with 8-oxoGua and
8-oxodGuo in the presence and absence of uricase solution
and no significant difference was found in the electrochem-
ical signals. A peak related to products from UA digestion
was detected at a retention time of ∼9.2 min, Fig. 3(2-A),
and is almost eliminated after SPE, Fig. 3(2-B). It was con-
cluded that digestion of UA by uricase is very efficient
and even causes a slight increase in the 8-oxoGua peak
current, Fig. 3(2-B), compared with that without uricase,
Fig. 3(1-B)).
For SPE procedure without uricase digestion, quantifi-
cation of 8-oxoGua and 8-oxodGuo in eluate solutions
compared to original peaks before SPE gave minimum
recovery rates around 65% for 8-oxoGua and 8-oxodG.
Anyway, this calculation gives only apparent recovery rates
since 8-oxoGua peak before SPE could not be quantified
correctly due to UA interference. After uricase digestion of
UA, it was possible to quantify both peaks before and after
SPE as presented in Table 1. Recoveries for each mixture
gave median recovery rates of 73 ± 3% for 8-oxoGua and
71± 3% for 8-oxodGuo (four determinations).
In the wash solutions, an 8-oxoGua peak was also detected
which corresponded to a loss of about 10% but no peak was
detected for 8-oxodGuo. In the filtrate solutions neither of
these analytes was detected. Since no significant amounts of
8-oxoGua and 8-oxodGuo were found in the filtrate and wash
solutions it was concluded that the recovery of 8-oxoGua
and 8-oxodGuo retained in the adsorbent is not complete,
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Table 1
SPE recoveries for 8-oxoGua and 8-oxodGuo in standard mixturesa
Mixture 8-oxoGua
and 8-oxodGuo (nM)
Ip (8-oxoGua) (nA) Ip (8-oxodGuo) (nA)
Before SPE After SPE Recovery (%) Before SPE After SPE Recovery (%)
25 0.24 0.18 75 0.07 0.05 71
50 0.46 0.33 72 0.15 0.1 67
100 0.96 0.66 69 0.28 0.2 71
250 2.4 1.8 75 0.68 0.5 74
73 ± 3% 71 ± 3%
a After excess UA digestion by uricase.
probably due to the low percentage of methanol used in
the eluent (pH 6.1 50 mM phosphate buffer + 20% MeOH).
Increasing the amount of methanol in the eluent would cause
complete elution of 8-oxoGua and 8-oxodGuo but would
also cause the elution of other urine interferents. Thus, this
SPE procedure is a compromise between recovery of the
analytes of interest and retention of undesired interferents.
This result should be taken into account when the final goal
is the development of a selective and lower detection limit
method for 8-oxoGua and 8-oxodGuo in urine with reduced
costs in sample pre-treatment.
3.5. Electrochemical detection of 8-oxoGua and
8-oxodGuo in urine samples
The method developed was tested in urine samples from
children (3–8 years old) with metabolic disorders, in order
to verify its ability to detect 8-oxoGua and 8-oxodGuo.
In Fig. 4A is presented the chromatogram obtained from
one of the urine samples directly injected after SPE treatment
(full line) and the chromatogram obtained from a 100 nM
standard mixture of UA, 8-oxoGua and 8oxodG (dotted
line). Comparing the urine chromatogram with the standard
mixture it can be concluded that UA was completely re-
moved from urine by uricase since otherwise, a peak from
UA in urine would appear at a retention time of 2.3 min. A
peak at a retention time of 3.4 min appears in urine sample
attributed to the presence of 8-oxoGua. In order to confirm
that this peak is due to 8-oxoGua, urine was spiked with
a 250 nM 8-oxoGua standard. Fig. 4B shows that the peak
at retention time 3.4 min increases (dotted line). Also, this
urine was analysed at two different potentials, +0.5 and
+0.35 V versus ISAAC and the peak current ratio obtained
was 1.6± 0.5 (two injections performed for each potential).
Peak current ratio from standard 8-oxoGua injection for
these two potentials was 1.5, as can be seen from hydrody-
namic voltammogram of 8-oxoGua in Fig. 1. These similar
values found for peak current ratio at different potentials in
the standard solution and in the urine sample give further
evidence that the urine peak at 3.4 min can be attributed to
8-oxoGua. The concentration of 8-oxoGua was found to be
∼360 nM, calculated from a calibration curve obtained by
injection of 8-oxoGua standards on the same day. However,
the purity of the peak was not confirmed since no spec-
troscopic information can be obtained due primarily to the
very low concentration of 8-oxoGua, but also because UV
spectra shows an intense peak of hypoxanthine at the same
retention time as 8-oxoGua, 3.4 min. In order to ensure that
hypoxanthine would not constitute an artefact in the electro-
chemical detection of 8-oxoGua, control experiments were
performed and it was confirmed that at the applied working
potential, hypoxanthine does not give any electrochemical
signal [55] and does not interfere at all in 8-oxoGua signal.
No 8-oxodGuo was detected in this urine sample as no
peak at the retention time of 8-oxodGuo (tR = 10.9 min)
was found. Nevertheless, when the urine was spiked with
a 250 nM 8-oxodGuo standard, a new clearly-defined peak
Fig. 4. (A) Chromatograms obtained from ( ) 10l injection of a 100 nM
standard mixture of UA, 8-oxoGua and 8-oxodGuo and ( ) 10l injection
of an urine sample from a child with metabolic disorders after being pro-
cessed by SPE. Same urine sample ( ) before and ( ) after being spiked
with 250 nM standard solutions of (B) 8-oxoGua and (C) 8-oxodGuo.
Mobile phase: 50 mM phosphate buffer + 6% MeOH + 2 mM KCl, final
pH 6.2.
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appeared at a retention time 10.9 min, Fig. 4C (dotted line)
which is evidence that in original urine no 8-oxodGuo
was present in a detectable amount, otherwise a peak
would appear as in the spiked urine. Undetectable levels
of 8-oxodGuo in urine, whilst 8-oxoGua was detected, can
be explained taking into account recent studies, applying
methodologies able to detect simultaneously 8-oxoGua and
8-oxodGuo in urine, where 8-oxoGua levels were found
to be always higher than 8-oxodGuo [22,23,44,49]. This
is also in good agreement with studies concerning DNA
damage repair mechanisms that show the primary DNA
repair pathway excises the base and not the nucleoside
[38–40]. On the other hand, looking at the intensity of
the peak for 8-oxodGuo in the 100 nM standard mixture,
Fig. 4A (dotted line), it can be seen that if 8-oxodGuo were
present in this urine at a level below 100 nM (which is
quite possible) it would not be detectable since the standard
peak is below the baseline. In fact, due to the great com-
plexity of urine samples, the background current increases
and the limits of detection in such complicated matrix
also increase about 100 times. From calibration curves ob-
tained by spiking urine with 8-oxoGua standards, a LOD of
80 nM for 8-oxoGua (Ip (nA) = 0.010 × 8-oxoGua nM−1;
R2 = 0.9994, S.D. = 0.237, N = 4) was found.
These results in urine demonstrated that there is no effect
of the urine matrix on the retention times of 8-oxoGua and
8-oxodGuo because they are the same in standard mixture
and in spiked urine.
In order to show better, the complexity and also inter-
individual variability of urine samples, results from a
65-year-old person suffering from Cognitive Deficit, are
presented in Fig. 5. This urine was processed by SPE
Fig. 5. Chromatograms obtained from 10l injection of an urine sample
from a 65-year-old person with cognitive deficit after being processed
with two different SPE octadecyl phase cartridges: (A) C18 cartridges;
(B) C18ec (ec, encapped) cartridges, ( ) before and ( ) after being
spiked with a 25 nM standard solution of 8-oxoGua. Mobile phase: 50 mM
phosphate buffer + 6% MeOH + 2 mM KCl, final pH 6.2.
in same way as described in Section 2.3.1 applying two
types of SPE cartridges: a C18 octadecyl phase adsorbent
(Fig. 5A) and a C18ec octadecyl phase adsorbent, were ec
means endcapped silanol groups (Fig. 5B). As can be seen,
a slight difference related with the capping chemistry of
the SPE cartridges used to process urine leads to a strong
difference in the cleaning of the matrix. In fact, even with
the same polarity range as C18 cartridges, these C18ec
cartridges do not interact with the polar groups of some
analytes, which explains the lesser number of compounds
retained. With end-capped C18ec cartridges it is possible
to eliminate more components from urine which allows a
chromatogram with a lower background current (Fig. 5B)
when compared to the one obtained for urine processed
with C18 adsorbent (Fig. 5A). A peak at same retention
time as 8-oxoGua, ∼3.4 min, was detected in urine treated
with both SPE cartridges, but in urine cleaned by C18 ad-
sorbent, the complexity is bigger and 8-oxoG peak is not
well resolved from neighbour ones. On contrary, in urine
treated with C18ec adsorbent, the peak for 8-oxoGua is
much better resolved. The identity of the peak was con-
firmed by a spiking of a 25 nM standard 8-oxoGua (Fig. 5B,
dotted line) and quantification by the standards addition
method gave a concentration of 7 nM for 8-oxoGua in this
urine. However, it should be remembered that C18ec adsor-
bents remove more components, including more 8-oxoGua,
which constitutes a drawback to their use, in comparison
with C18 octadecyl phase adsorbent cartridges, if the final
goal is the quantification of the analyte of interest.
4. Conclusion
Simultaneous detection of urinary levels of 8-oxoGua and
8-oxodGuo, besides reducing analysis time and being less
demanding on resources, may give further insight into the
relative significance of the use of 8-oxoGua and 8-oxodGuo
as biomarkers of DNA oxidative damage and of oxidative
stress. It is widely accepted that 8-oxoGua and 8-oxodGuo
are major products of DNA oxidative damage and can be en-
zymatically repaired being excreted into urine at steady-state
levels below 100 nM. There is still a great need for good
methodologies for their simultaneous detection in urine that
reflects the big difficulty of 8-oxoGua detection in urine sam-
ples due to the interference of UA, a strong interferent ex-
creted in urine in 104-fold higher concentrations. The present
work describes a methodology based on HPLC-ECD for de-
tection of 8-oxoGua in the presence of UA with a good sepa-
ration factor between 8-oxoGua and UA (α = 3.7), enabling
a LOD for both analytes below 1 nM in standard mixtures.
The method was applied to urine samples after uricase
digestion of excess uric acid and one-step solid phase ex-
traction. It was possible to detect and quantify the presence
of 8-oxoGua in urine and to confirm that UA was eliminated
after uricase degradation and SPE. The LOD found in urine
samples for 8-oxoGua was 80 nM, a value higher than in
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standard mixtures, which is due to the increase in the back-
ground current. Due to the complexity and inter-individual
variability of urine samples, the main application of the
present methodology when applied to urine is the simulta-
neous detection of 8-oxoGua and 8-oxodGuo, reducing as
much as possible the sample pre-treatment steps.
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